Gyre Therapeutics (GYRE) Earnings Analysis
Gyre Therapeutics (GYRE) next reports earnings on 2026-08-10, consensus EPS -0.08 USD. Last quarter (2026-05-07) it beat with EPS -0.05 USD vs -0.06 USD est (+16.7%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -80.38.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GYRE next report earnings?
| Next earnings date | 2026-08-10 |
|---|---|
| Consensus EPS estimate | -0.08 USD |
| Revenue estimate | 0.03B |
GYRE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.05 USD | -0.06 USD | +16.7% | Beat |
| 2026-03-12 | 0.04 USD | 0.05667 USD | -29.4% | Miss |
| 2025-11-07 | 0.06 USD | 0.05 USD | +20% | Beat |
| 2025-08-11 | 0.02 USD | 0.03 USD | -33.3% | Miss |
| 2025-05-09 | 0.03 USD | 0.03 USD | 0% | Beat |
| 2025-03-17 | 0.01 USD | 0.04 USD | -75% | Miss |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
GYRE valuation and analyst view
| Trailing P/E | -80.38 |
|---|---|
| Trailing EPS | -0.06885 USD |
| Price / book | 5.35 |
| Dividend yield | 0.00% |
| Market cap | 0.54B |
| Analyst consensus | Buy (1 buy / 0 hold / 0 sell) |
| Avg price target | 17 USD |
Related research pages
Frequently asked questions
When is Gyre Therapeutics (GYRE)'s next earnings date?
Gyre Therapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.08 USD and revenue estimate of 0.03B.
Did GYRE beat earnings last quarter?
In its 2026-05-07 report, GYRE posted EPS of -0.05 USD versus a -0.06 USD estimate — a beat of 16.7%.
What is GYRE's earnings track record?
Over the last 6 reported quarters with consensus data, GYRE beat estimates 3 times (50%).
What is GYRE's current P/E ratio and EPS?
GYRE trades at a trailing P/E of -80.38 on trailing EPS of -0.06884797161085046 USD.
What do analysts rate GYRE?
Analyst consensus is "Buy" across 1 ratings (0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 17 USD.